Updated from their original publication in 2004, these cancer genetic counseling recommendations describe the medical, psychosocial, and ethical ramifications of counseling at-risk individuals through genetic cancer risk assessment with or without genetic testing. They were developed by members of the Practice Issues Subcommittee of the National Society of Genetic Counselors Familial Cancer Risk Counseling Special Interest Group. The information contained in this document is derived from extensive review of the current literature on cancer genetic risk assessment and counseling as well as the personal expertise of genetic counselors specializing in cancer genetics. The recommendations are intended to provide information about the process of genetic counseling and risk assessment for hereditary cancer disorders rather than specific information about individual syndromes. Essential components include the intake, cancer risk assessment, genetic testing for an inherited cancer syndrome, informed consent, disclosure of genetic test results, and psychosocial assessment. These recommendations should not be construed as dictating an exclusive course of management, nor does use of such recommendations guarantee a particular outcome. These recommendations do not displace a health care provider’s professional judgment based on the clinical circumstances of a client.
This is a preview of subscription content, access via your institution.
Amir, E., Freedman, O. C., Seruga, B., & Evans, D. G. (2010). Assessing women at high risk of breast cancer: a review of risk assessment models. Journal of the National Cancer Institute, 102(10), 680–691.
American College of Medical Genetics (ACMG). (1995). Genetic Testing in Children and Adolescents, Points to Consider: Ethical, Legal and Psychosocial Implications. American Journal of Human Genetics, 57, 1233–1241.
American Society of Clinical Oncology (ASCO). (2003). ASCO policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397–2406.
American Society of Human Genetics (ASHG) Social Issues Subcommittee on Familial Disclosure. (1998). ASHG statement. Professional disclosure of familial genetic information. American Journal of Human Genetics, 62(2), 474–483.
Antoniou, A. C., Pharoah, P. P., Smith, P., et al. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580–90.
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 376(9737), 245–251.
Baum, A., Friedman, A. L., & Zakowski, S. G. (1997). Stress and genetic testing for disease risk. Health Psychology, 16(1), 8–19.
Bennett, R. L. (1999). The practical guide to the genetic family history. New York: Wiley.
Bennett, R. L. (2010). The practical guide to the genetic family history (2nd ed.). Hoboken: Wiley-Blackwell.
Bennett, R. L., French, K. S., Resta, R. G., & Doyle, D. L. (2008). Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 17(5), 424–433.
Braithwaite, D., Emery, J., Walter, F., Prevost, A. T., & Sutton, S. (2006). Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Familial Cancer, 5(1), 61–75.
Brown, K. L., Moglia, D. M., & Grumet, S. (2006). Genetic counseling for breast cancer risk: general concepts, challenging themes and future directions. Breast Disease, 27, 69–96.
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology, 28(3), 375–379.
Chivers-Seymour, K., Addington-Hall, J., Lucassen, A., & Foster, C. (2010). What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. Journal of Genetic Counseling, 19(4), 330–342.
Claus, E. B., Risch, N., & Thompson, W. D. (1993). The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment, 28(2), 115–20.
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., (1997). BRCA1 mutations in women attending clinics that evaluate breast cancer risk. The New England Journal of Medicine 336, 1409–1415.
Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B., & Nash, J. (1997). Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychology, 16(1), 63–72.
Culver, J. O., Lowstuter, K., & Bowling, L. (2006). Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Disease, 27, 5–20.
Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Journal of the American Medical Association, 304(9), 967–975.
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., Kalkbrenner, K. J., et al. (2000). Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. Journal of Clinical Oncology, 18(10), 2135–2142.
Edwards, A., Gray, J., Clarke, A., Dundon, J., Elwyn, G., Gaff, C., et al. (2008). Interventions to improve risk communication in clinical genetics: systematic review. Patient Education and Counseling, 71(1), 4–25.
Eng, C., Hampel, H., & de la Chapelle, A. (2001). Genetic testing for cancer predisposition. Annual Review of Medicine, 52, 371–400.
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.
Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006). Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. Journal of Medical Genetics, 43, 289–294.
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute, 90(18), 1371–1388.
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123–134.
Forrest, L. E., Burke, J., Bacic, S., et al. (2008). Increased genetic counseling support improves communication of genetic information in families. Genetics in Medicine, 10(3), 167–72.
Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood M. E., Mullineau L., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology 16, 2417–2425.
Gail, M. H., Brinton, L. A., Byar, D. P., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81(24), 1879–86.
Gallo, A. M., Angst, D. B., & Knafl, K. A. (2009). Disclosure of genetic information within families. The American Journal of Nursing, 109(4), 65–69.
Gaff, L., & Bylund, C. (Eds.). (2010). Family communication about genetics. New York: Oxford University Press.
Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B. B., Wilfond, B., et al. (1997). Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. Journal of the American Medical Association, 277(18), 1467–1474.
Hampel, H., Sweet, K., Westman, J. A., Offit, K., & Eng, C. (2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. Journal of Medical Genetics, 41(2), 81–91.
Hudson, K., Javitt, G., Burke, W., Byers, P. A., & Society of Human Genetics (ASHG) Social Issues Committee. (2007). ASHG Statement* on direct-to-consumer genetic testing in the United States. Journal of Obstetrics and Gynecology, 110(6), 1392–1395.
Jenkins, J., Calzone, K. A., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine, 9(8), 487–95.
Kenen, R. H., Shapiro, P. J., Friedman, S., & Coyne, J. C. (2007). Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psycho-Oncology, 16(8), 763–771.
Kloos, R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., et al. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19(6), 565–612.
Koehly, L. M., Peters, J. A., Kenen, R., Hoskins, L. M., Ersig, A. L., Kuhn, N. R., et al. (2009). Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. American Journal of Public Health, 99(12), 2203–2209.
Konstantopoulou, I., Pertesi, M., Fostira, F., Grivas, A., & Yannoukakos, D. (2009). Hereditary cancer predisposition syndromes and preimplantation genetic diagnosis: where are we now? Journal of Balkan Union Oncology, 14(Suppl 1), S187–192.
Lerman, C., Biesecker, B., Benkendorf, J. L., Kerner, J., Gomez-Caminero, A., Hughes, C., & Reed, M. M. (1997). Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. Journal of the National Cancer Institute, 89(2), 148–157.
Ligtenberg, M. J., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nature Genetics, 41(1), 112–117.
Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. Journal of the American Medical Association, 296(12), 1507–17.
Lindor, N. M., McMaster, M. L., Lindor, C. J., & Greene, M. H. (2008). Concise handbook of familial cancer susceptibility syndromes—second edition. Journal of the National Cancer Institute. Monographs, 38, 1–93.
Lindor, N. M., Johnson, K. J., Harvey, H., Pankratz, V. S., Domchek, S. M., Hunt, K., Wilson, M., Smith, C. S., & Couch, F. (2010). Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Familial Cancer, 9, 405–402.
McKinnon, W., Naud, S., Ashikaga, T., Colletti, R., & Wood, M. (2007). Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. Journal of Genetic Counseling, 16(4), 433–456.
Meiser, B. (2005). Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology, 14(12), 1060–1074.
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328–35.
National Cancer Institute (NCI) (2010). PDQ® Cancer Genetics Risk Assessment and Counseling. Retrieved from https://doi.org/cancer.gov/cancertopics/pdq/genetics/risk-assessment-andcounseling/HealthProfessional.
National Comprehensive Cancer Network (NCCN) 2 (2011) NCCN Clinical Practice Guidelines in Oncology, Colorectal Cancer Screening. Retrieved from https://doi.org/www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf.
National Society of Genetic Counselors. (2007). NSGC Position Statement: Direct to Consumer Genetic Testing. Retrieved from https://doi.org/www.nsgc.org/Advocacy/PositionStatements/tabid/107/Default.aspx.
Nelson, R. M., Botkjin, J. R., Kodish, E. D., Levetown, M., Truman, J. T., Wilfond, B. S., et al. (2001). Ethical issues with genetic testing in pediatrics. Pediatrics, 107(6), 1451–1455.
Offit, K., Kohut, K., Clagett, B., Wadsworth, E. A., Lafaro, K. J., Cummings, S., et al. (2006). Cancer genetic testing and assisted reproduction. Journal of Clinical Oncology, 24(29), 4775–4782.
Offit, K., Groeger, E., Turner, S., Wadworth, E. A., & Weiser, M. A. (2004). The “duty to warn” a patient’s family members about hereditary disease risks. Journal of the American Medical Association, 292(12), 1469–73.
Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62(1), 145–58.
Patenaude, A. F., & Juliean-Reynier, C. (2008). Cancer genetic testing: current and emerging issues. Psycho-Oncology, 17(8), 733–736.
Pieterse, A. H., Ausems, M. G., Van Dulmen, A. M., Beemer, F. A., & Bensing, J. M. (2005). Initial cancer genetic counseling consultation: change in counselees’ cognitions and anxiety, and association with addressing their needs and preferences. American Genetics in Medicine, 137(1), 27–35.
Pieterse, A. H., van Dulmen, A. M., Beemer, F. A., Bensing, J. M., & Ausems, M. G. (2007). Cancer genetic counseling: communication and counselees’ post-visit satisfaction, cognitions, anxiety, and needs fulfillment. Journal of Genetic Counseling, 16(1), 85–96.
Pilarski, R. (2009). Cowden syndrome: a critical review of the clinical literature. Journal of Genetic Counseling, 18(1), 13–27.
Quillin, J. M., Bodurtha, J. N., Siminoff, L. A., & Smith, T. J. (2010). Exploring hereditary cancer among dying cancer patients-a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. Journal of Genetic Counseling, 19(5), 497–525.
Qureshi N, Wilson, B., Santaguida P., Carroll J., Allanson J., Ruiz Culebro C., et al. (2007). Collection and Use of Cancer Family History in Primary Care. Evidence Report/Technology Assessment No. 159 (prepared by the McMaster University Evidence-based Practice Center, under Contract No. 290-02-0020). Rockville, MD: Agency for Healthcare Research and Quality, AHRQ Publication No. 08-E001.
Rich, E. C., Burke, W., Heaton, C. J., Haga, S., Pinsky, L., Short, M. P., et al. (2004). Reconsidering the family history in primary care. Journal of General Internal Medicine, 19(3), 273–280.
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893–901.
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology, 28(20), 3219–3226.
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., American Cancer Society Breast Cancer Advisory Group, et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. A Cancer Journal for Clinicians, 57(2), 75–89.
Schneider, K. A. (2002). Counseling about cancer: Strategies for genetic counseling (2nd ed.). New York: Wiley-Liss.
Schneider, K. A., DiGianni, L. M., Patenaude, A. F., Klar, N., Stopfer, J. E., Calzone, K. A., et al. (2004). Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genetic Testing and Molecular Biomarkers, 8(3), 222–8.
Schneider, K. A., Chittenden, A. B., Branda, K. J., Keenan, M. A., Joffe, S., Patenaude, A. F., et al. (2006). Ethical issues in cancer genetics: whose information is it? Journal of Genetic Counseling, 15(6), 491–503.
Sivell, S., Iredale, R., Gray, J., & Coles, B. (2007). Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database of Systematic Reviews(2), CD003721.
Spits, C., De Rycke, M., Van Ranst, N., Verpoest, W., Lissens, W., Van Steirteghem, A., et al. (2007). Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenatal Diagnosis, 27(5), 447–56.
Stultiens, B. P., Nys, H., Cassiman, J. J., & Dierickx, K. (2006). Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clinical Genetics, 70, 374–381.
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. Journal of Genetic Counseling, 13(2), 83–114.
Trepanier, A., Allain, D., & Cohen S. (2011). Assessing the use of various service delivery models in cancer genetics. Abstract 366. American College of Medical Genetics.
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 376(9737), 235–244.
Tyrer, J., Duffy, S. W., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23(7), 1111–30.
United States Preventive Services Task Force (USPSTF). (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 143(5), 355–61.
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–8.
Weissman, S. M., Bellcross, C., Bittner, C. C., Freivogel, M. E., Haidle, J. L., Kaurah, P., et al. (2011). Genetic counseling considerations in the evaluation of families for Lynch syndrome- a review. Journal of Genetic Counseling, 20(1), 5–19.
Weitzel, J. N., Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, J. O., Blazer, K. R., et al. (2007). Limited family structure and BRCA gene mutation status in single cases of breast cancer. Journal of the American Medical Association, 297(23), 2587–2595.
Wham, D., Vu, T., Chan-Smutko, G., Kobelka, C., Urbauer, D., & Heald, B. (2010). Assessment of clinical practices among cancer genetic counselors. Familial Cancer, 9(3), 459–468.
The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and are subject to change without notice as advances emerge.
In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by NSGC for educational and informational purposes only, and NSGC does not “approve” or “endorse” any specific methods, practices, or sources of information.
The National Society of Genetic Counselors (NSGC) is the primary leader for the genetic counseling profession. Its mission is to advance the various roles of genetic counselors in health care by fostering education, research, and public policy to ensure the availability of quality genetic services. To that end, the Society promotes the development of practice guidelines for genetic counselors and others who provide genetic counseling services. The purpose of this document is to present a current and comprehensive set of practice recommendations for effective genetic cancer risk assessment, counseling, and testing. These guidelines were developed by the NSGC’s Familial Cancer Risk Counseling Special Interest Group which includes NSGC members providing cancer genetics services.
About this article
Cite this article
Riley, B.D., Culver, J.O., Skrzynia, C. et al. Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors. J Genet Counsel 21, 151–161 (2012). https://doi.org/10.1007/s10897-011-9462-x
- Cancer genetic counseling
- Risk assessment
- Genetic testing
- Family history
- Psychosocial assessment
- Hereditary cancer
- Informed consent